Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H15Cl3N2O.HNO3 |
Molecular Weight | 444.696 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[N+]([O-])=O.ClC1=CC=C(COC(CN2C=CN=C2)C3=C(Cl)C=C(Cl)C=C3)C=C1
InChI
InChIKey=DDXORDQKGIZAME-UHFFFAOYSA-N
InChI=1S/C18H15Cl3N2O.HNO3/c19-14-3-1-13(2-4-14)11-24-18(10-23-8-7-22-12-23)16-6-5-15(20)9-17(16)21;2-1(3)4/h1-9,12,18H,10-11H2;(H,2,3,4)
Econazole (commonly used as the nitrate salt) is an antifungal medication of the imidazole class. It is a broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally. Sold under the brand name Ecoza among others, it is indicated for the treatment of interdigital tinea
pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and
Epidermophyton floccosum in patients 12 years of age and older. Econazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Econazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
17.9 nM [Kd] | |||
Target ID: CHEMBL612649 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | ECOZA Approved UseEcoza (econazole nitrate) topical foam, 1%, is indicated for the treatment of interdigital tinea
pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton
floccosum in patients 12 years of age and older. Launch Date1982 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
417 pg/mL |
24 mg 1 times / day steady-state, topical dose: 24 mg route of administration: Topical experiment type: STEADY-STATE co-administered: |
ECONAZOLE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3440 pg × h/mL |
24 mg 1 times / day steady-state, topical dose: 24 mg route of administration: Topical experiment type: STEADY-STATE co-administered: |
ECONAZOLE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
53 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32410819 |
150 mg single, vaginal dose: 150 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
ECONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
81.77 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32410819 |
150 mg 1 times / day multiple, vaginal dose: 150 mg route of administration: Vaginal experiment type: MULTIPLE co-administered: |
ECONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 5.0 |
no | |||
Page: 5.0 |
no | |||
Page: 5.0 |
no | |||
Page: 5.0 |
no | |||
Page: 5.0 |
no | |||
Page: 5.0 |
no | |||
Page: 5.0 |
no | |||
Page: 5.0 |
no | |||
Page: 5.0 |
no | |||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Fatty acids inhibit anion secretion in rat colon: apical and basolateral action sites. | 2001 Jul |
|
Azole-antifungal binding to a novel cytochrome P450 from Mycobacterium tuberculosis: implications for treatment of tuberculosis. | 2001 Jun 15 |
|
Comparison of in vitro activities of amphotericin, clotrimazole, econazole, miconazole, and nystatin against Fusarium oxysporum. | 2001 May |
|
In vitro activity of 6 antifungal agents on candida species isolated as causative agents from vaginal and other clinical specimens. | 2001 Oct |
|
Pharmacological modulation of monovalent cation currents through the epithelial Ca2+ channel ECaC1. | 2001 Oct |
|
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. | 2002 Apr 19 |
|
Assessing pregnancy risks of azole antifungals using a high throughput aromatase inhibition assay. | 2002 Aug |
|
Hepatoprotective and therapeutic effects of tetramethylpyrazine on acute econazole-induced liver injury. | 2002 Jun |
|
Strategy for the development of automated methods involving dialysis and trace enrichment as on-line sample preparation for the determination of basic drugs in plasma by liquid chromatography. | 2002 Mar 1 |
|
Sensitivity of myeloid leukemia cells to calcium influx blockade: application to bone marrow purging. | 2002 Oct |
|
Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes. | 2002 Oct |
|
Pituitary adenylate cyclase-activating polypeptide induces a sustained increase in intracellular free Ca(2+) concentration and catechol amine release by activating Ca(2+) influx via receptor-stimulated Ca(2+) entry, independent of store-operated Ca(2+) channels, and voltage-dependent Ca(2+) channels in bovine adrenal medullary chromaffin cells. | 2002 Sep |
|
Effect of epidermal growth factor on phosphate uptake in renal proximal tubule cells: involvement of PKC, MAPK, and cPLA2. | 2003 |
|
Inhibition of heme crystal growth by antimalarials and other compounds: implications for drug discovery. | 2003 Dec 1 |
|
A population-based case-control teratological study of vaginal econazole treatment during pregnancy. | 2003 Dec 10 |
|
Enhanced econazole penetration into human nail by 2-n-nonyl-1,3-dioxolane. | 2003 Jan |
|
Ligand-activated signal transduction in the 2-cell embryo. | 2003 Jul |
|
Effects of cytochrome P450 inhibitors on agonist-induced Ca2+ responses and production of NO and PGI2 in vascular endothelial cells. | 2003 Jun |
|
Candidemia and the susceptibility pattern of Candida isolates in blood. | 2003 Oct |
|
Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. | 2004 Apr 15 |
|
The calcium influx pathway in rat olfactory ensheathing cells shows TRPC channel pharmacology. | 2004 Oct 8 |
|
P2Y2-receptor-mediated activation of a contralateral, lanthanide-sensitive calcium entry pathway in the human airway epithelium. | 2004 Sep |
|
[Congenital cutaneous candidiasis: a case report and review]. | 2005 Dec |
|
Altered expression profile of mycobacterial surface glycopeptidolipids following treatment with the antifungal azole inhibitors econazole and clotrimazole. | 2005 Jun |
|
Signaling pathways in the biphasic effect of ANG II on Na+/H+ exchanger in T84 cells. | 2005 May |
|
In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv. | 2005 Oct 1 |
|
Econazole induces increases in free intracellular Ca2+ concentrations in human osteosarcoma cells. | 2005 Sep |
|
Nano-encapsulation of azole antifungals: potential applications to improve oral drug delivery. | 2005 Sep 14 |
|
Single-dose sertaconazole vaginal tablet treatment of vulvovaginal candidiasis. | 2006 Jun |
|
What is the best way to treat tinea cruris? | 2006 Mar |
|
Antimycotic influence of beta-cyclodextrin complexes--in vitro measurements using laser nephelometry in microtiter plates. | 2006 Mar 27 |
Patents
Sample Use Guides
Topical foam, 1% is for topical use only. Ecoza topical foam, 1% is not for oral,
ophthalmic, or intravaginal use.
Ecoza topical foam, 1% should be applied to cover affected areas once daily for 4 weeks.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16543605
Curator's Comment: Econazole inhibited the growth of all isolates of Trichophyton species in low concentrations of 2-4 micrograms/ml except one isolate of T. rubrum which was inhibited by a concentration ug/ml. https://www.ncbi.nlm.nih.gov/pubmed/2737705
Minimum inhibitory concentrations (MIC) of econazole against Mycobacterium avium complex (MAC) and and a minimum bacteriocidal concentration was 4 ug/ml.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C514
Created by
admin on Fri Dec 15 15:19:13 GMT 2023 , Edited by admin on Fri Dec 15 15:19:13 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
68589
Created by
admin on Fri Dec 15 15:19:13 GMT 2023 , Edited by admin on Fri Dec 15 15:19:13 GMT 2023
|
PRIMARY | |||
|
C47506
Created by
admin on Fri Dec 15 15:19:13 GMT 2023 , Edited by admin on Fri Dec 15 15:19:13 GMT 2023
|
PRIMARY | |||
|
24169-02-6
Created by
admin on Fri Dec 15 15:19:13 GMT 2023 , Edited by admin on Fri Dec 15 15:19:13 GMT 2023
|
PRIMARY | |||
|
68797-31-9
Created by
admin on Fri Dec 15 15:19:13 GMT 2023 , Edited by admin on Fri Dec 15 15:19:13 GMT 2023
|
SUPERSEDED | |||
|
246-053-5
Created by
admin on Fri Dec 15 15:19:13 GMT 2023 , Edited by admin on Fri Dec 15 15:19:13 GMT 2023
|
PRIMARY | |||
|
100000092986
Created by
admin on Fri Dec 15 15:19:13 GMT 2023 , Edited by admin on Fri Dec 15 15:19:13 GMT 2023
|
PRIMARY | |||
|
m4819
Created by
admin on Fri Dec 15 15:19:13 GMT 2023 , Edited by admin on Fri Dec 15 15:19:13 GMT 2023
|
PRIMARY | Merck Index | ||
|
H438WYN10E
Created by
admin on Fri Dec 15 15:19:13 GMT 2023 , Edited by admin on Fri Dec 15 15:19:13 GMT 2023
|
PRIMARY | |||
|
4755
Created by
admin on Fri Dec 15 15:19:13 GMT 2023 , Edited by admin on Fri Dec 15 15:19:13 GMT 2023
|
PRIMARY | |||
|
DTXSID6025226
Created by
admin on Fri Dec 15 15:19:13 GMT 2023 , Edited by admin on Fri Dec 15 15:19:13 GMT 2023
|
PRIMARY | |||
|
SUB01855MIG
Created by
admin on Fri Dec 15 15:19:13 GMT 2023 , Edited by admin on Fri Dec 15 15:19:13 GMT 2023
|
PRIMARY | |||
|
DBSALT002838
Created by
admin on Fri Dec 15 15:19:13 GMT 2023 , Edited by admin on Fri Dec 15 15:19:13 GMT 2023
|
PRIMARY | |||
|
H438WYN10E
Created by
admin on Fri Dec 15 15:19:13 GMT 2023 , Edited by admin on Fri Dec 15 15:19:13 GMT 2023
|
PRIMARY | |||
|
CHEMBL808
Created by
admin on Fri Dec 15 15:19:13 GMT 2023 , Edited by admin on Fri Dec 15 15:19:13 GMT 2023
|
PRIMARY | |||
|
1231808
Created by
admin on Fri Dec 15 15:19:13 GMT 2023 , Edited by admin on Fri Dec 15 15:19:13 GMT 2023
|
PRIMARY | |||
|
142434
Created by
admin on Fri Dec 15 15:19:13 GMT 2023 , Edited by admin on Fri Dec 15 15:19:13 GMT 2023
|
PRIMARY | RxNorm |
ACTIVE MOIETY
SUBSTANCE RECORD